OMAHA-003: opevesostat versus abiraterone or enzalutamide in previously treated metastatic castration-resistant prostate cancer

Phase 3, randomised, open-label trial of opevesostat in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Merck & Co. Primary endpoints: Overall survival in androgen receptor ligand binding domain mutation-positive participants and Overall survival in androgen receptor ligand binding domain mutation-negative participants. Planned start Mar 2024; status: authorised.